Shares of Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) were down 1.4% during mid-day trading on Tuesday . The company traded as low as C$8.74 and last traded at C$8.74. Approximately 200 shares traded hands during trading, a decline of 66% from the average daily volume of 586 shares. The stock had previously closed at C$8.86.
Neuren Pharmaceuticals Trading Down 1.4 %
The stock’s fifty day simple moving average is C$8.11 and its 200-day simple moving average is C$8.67.
Neuren Pharmaceuticals Company Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Read More
- Five stocks we like better than Neuren Pharmaceuticals
- How to buy stock: A step-by-step guide for beginners
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- About the Markup Calculator
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
